Forte Biosciences Inc.
16.55
1.93 (13.20%)
At close: Jan 15, 2025, 1:43 PM

Company Description

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States.

It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata.

The company is headquartered in Dallas, Texas.

Forte Biosciences Inc.
Forte Biosciences Inc. logo
Country United States
IPO Date Apr 13, 2017
Industry Biotechnology
Sector Healthcare
Employees 11
CEO Dr. Paul A. Wagner Ph.D.

Contact Details

Address:
3060 Pegasus Park Drive
Dallas, Texas
United States
Website https://www.fortebiorx.com

Stock Details

Ticker Symbol FBRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001419041
CUSIP Number 34962G109
ISIN Number US34962G1094
Employer ID 26-1243872
SIC Code 2834

Key Executives

Name Position
Dr. Paul A. Wagner Ph.D. Chief Executive Officer, President & Chairman
Antony A. Riley CPA Chief Financial Officer
Christopher Roenfeldt Chief Operating Officer
Dr. Barbara K. Finck M.D. Chief Medical Clinician & Director
Steven Ruhl Chief Technical Officer

Latest SEC Filings

Date Type Title
Jan 10, 2025 SCHEDULE 13G Filing
Jan 02, 2025 4 Filing
Jan 02, 2025 4 Filing
Dec 31, 2024 DEF 14A Filing
Dec 20, 2024 424B3 Filing
Dec 13, 2024 S-3 Filing
Dec 06, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Dec 03, 2024 8-K Current Report
Nov 22, 2024 4 Filing
Nov 20, 2024 8-K Current Report